AVIR
Price
$3.16
Change
-$0.05 (-1.56%)
Updated
Jun 13 closing price
Capitalization
270.43M
53 days until earnings call
KALV
Price
$12.96
Change
-$0.13 (-0.99%)
Updated
Jun 13 closing price
Capitalization
644.31M
19 days until earnings call
Interact to see
Advertisement

AVIR vs KALV

Header iconAVIR vs KALV Comparison
Open Charts AVIR vs KALVBanner chart's image
Atea Pharmaceuticals
Price$3.16
Change-$0.05 (-1.56%)
Volume$340.71K
Capitalization270.43M
KalVista Pharmaceuticals
Price$12.96
Change-$0.13 (-0.99%)
Volume$772.13K
Capitalization644.31M
AVIR vs KALV Comparison Chart
Loading...
AVIR
Daily Signalchanged days ago
Gain/Loss if bought
Show more...
KALV
Daily Signalchanged days ago
Gain/Loss if bought
Show more...
View a ticker or compare two or three
VS
AVIR vs. KALV commentary
Jun 14, 2025

To compare these two companies we present long-term analysis, their fundamental ratings and make comparative short-term technical analysis which are presented below. The conclusion is AVIR is a Hold and KALV is a StrongBuy.

Interact to see
Advertisement
COMPARISON
Comparison
Jun 14, 2025
Stock price -- (AVIR: $3.16 vs. KALV: $12.96)
Brand notoriety: AVIR and KALV are both not notable
Both companies represent the Biotechnology industry
Current volume relative to the 65-day Moving Average: AVIR: 78% vs. KALV: 144%
Market capitalization -- AVIR: $270.43M vs. KALV: $644.31M
AVIR [@Biotechnology] is valued at $270.43M. KALV’s [@Biotechnology] market capitalization is $644.31M. The market cap for tickers in the [@Biotechnology] industry ranges from $355.9B to $0. The average market capitalization across the [@Biotechnology] industry is $2.45B.

Long-Term Analysis

It is best to consider a long-term outlook for a ticker by using Fundamental Analysis (FA) ratings. The rating of 1 to 100, where 1 is best and 100 is worst, is divided into thirds. The first third (a green rating of 1-33) indicates that the ticker is undervalued; the second third (a grey number between 34 and 66) means that the ticker is valued fairly; and the last third (red number of 67 to 100) reflects that the ticker is undervalued. We use an FA Score to show how many ratings show the ticker to be undervalued (green) or overvalued (red).

AVIR’s FA Score shows that 0 FA rating(s) are green whileKALV’s FA Score has 0 green FA rating(s).

  • AVIR’s FA Score: 0 green, 5 red.
  • KALV’s FA Score: 0 green, 5 red.
According to our system of comparison, AVIR is a better buy in the long-term than KALV.

Short-Term Analysis

It is best to consider a short-term outlook for a ticker by using Technical Analysis (TA) indicators. We use Odds of Success as the percentage of outcomes which confirm successful trade signals in the past.

If the Odds of Success (the likelihood of the continuation of a trend) for each indicator are greater than 50%, then the generated signal is confirmed. A green percentage from 90% to 51% indicates that the ticker is in a bullish trend. A red percentage from 90% - 51% indicates that the ticker is in a bearish trend. All grey percentages are below 50% and are considered not to confirm the trend signal.

AVIR’s TA Score shows that 6 TA indicator(s) are bullish while KALV’s TA Score has 5 bullish TA indicator(s).

  • AVIR’s TA Score: 6 bullish, 4 bearish.
  • KALV’s TA Score: 5 bullish, 5 bearish.
According to our system of comparison, AVIR is a better buy in the short-term than KALV.

Price Growth

AVIR (@Biotechnology) experienced а -0.63% price change this week, while KALV (@Biotechnology) price change was -9.78% for the same time period.

The average weekly price growth across all stocks in the @Biotechnology industry was -0.75%. For the same industry, the average monthly price growth was +12.94%, and the average quarterly price growth was +4.02%.

Reported Earning Dates

AVIR is expected to report earnings on Aug 06, 2025.

KALV is expected to report earnings on Sep 04, 2025.

Industries' Descriptions

@Biotechnology (-0.75% weekly)

Biotechnology involves genetic or protein engineering to produce medicines/therapies for treating and preventing ailments. The industry also provides crucial ingredients for diagnostics. This multi-billion-dollar industry is heavily focused on research and development, as companies attempt to continually come up with cutting-edge solutions for health. New discoveries for the treatment of diseases provide opportunities for growth for a company in this industry. Discoveries, however, must pass the regulatory approval from the U.S. Food and Drug Administration (FDA) before they can make it to markets. Amgen Inc., Gilead Sciences, Inc. and Celgene Corporation are examples of companies in this industry.

SUMMARIES
Loading...
FUNDAMENTALS
Fundamentals
KALV($644M) has a higher market cap than AVIR($270M). KALV YTD gains are higher at: 53.011 vs. AVIR (-5.672). KALV has higher annual earnings (EBITDA): -173.23M vs. AVIR (-192.53M). AVIR has more cash in the bank: 455M vs. KALV (253M). AVIR has less debt than KALV: AVIR (1.64M) vs KALV (5.78M). AVIR (0) and KALV (0) have equivalent revenues.
AVIRKALVAVIR / KALV
Capitalization270M644M42%
EBITDA-192.53M-173.23M111%
Gain YTD-5.67253.011-11%
P/E RatioN/AN/A-
Revenue00-
Total Cash455M253M180%
Total Debt1.64M5.78M28%
FUNDAMENTALS RATINGS
AVIR vs KALV: Fundamental Ratings
AVIR
KALV
OUTLOOK RATING
1..100
1716
VALUATION
overvalued / fair valued / undervalued
1..100
42
Fair valued
54
Fair valued
PROFIT vs RISK RATING
1..100
9593
SMR RATING
1..100
9196
PRICE GROWTH RATING
1..100
4542
P/E GROWTH RATING
1..100
95100
SEASONALITY SCORE
1..100
450

Tickeron ratings are formulated such that a rating of 1 designates the most successful stocks in a given industry, while a rating of 100 points to the least successful stocks for that industry.

AVIR's Valuation (42) in the Biotechnology industry is in the same range as KALV (54) in the Pharmaceuticals Other industry. This means that AVIR’s stock grew similarly to KALV’s over the last 12 months.

KALV's Profit vs Risk Rating (93) in the Pharmaceuticals Other industry is in the same range as AVIR (95) in the Biotechnology industry. This means that KALV’s stock grew similarly to AVIR’s over the last 12 months.

AVIR's SMR Rating (91) in the Biotechnology industry is in the same range as KALV (96) in the Pharmaceuticals Other industry. This means that AVIR’s stock grew similarly to KALV’s over the last 12 months.

KALV's Price Growth Rating (42) in the Pharmaceuticals Other industry is in the same range as AVIR (45) in the Biotechnology industry. This means that KALV’s stock grew similarly to AVIR’s over the last 12 months.

AVIR's P/E Growth Rating (95) in the Biotechnology industry is in the same range as KALV (100) in the Pharmaceuticals Other industry. This means that AVIR’s stock grew similarly to KALV’s over the last 12 months.

TECHNICAL ANALYSIS
Technical Analysis
AVIRKALV
RSI
ODDS (%)
Bearish Trend 1 day ago
83%
Bearish Trend 1 day ago
83%
Stochastic
ODDS (%)
Bearish Trend 1 day ago
90%
Bearish Trend 1 day ago
83%
Momentum
ODDS (%)
Bullish Trend 1 day ago
79%
Bullish Trend 1 day ago
80%
MACD
ODDS (%)
Bullish Trend 1 day ago
83%
Bullish Trend 1 day ago
82%
TrendWeek
ODDS (%)
Bearish Trend 1 day ago
84%
Bearish Trend 1 day ago
85%
TrendMonth
ODDS (%)
Bullish Trend 1 day ago
75%
Bullish Trend 1 day ago
84%
Advances
ODDS (%)
Bullish Trend 5 days ago
77%
Bullish Trend 6 days ago
79%
Declines
ODDS (%)
Bearish Trend 9 days ago
80%
Bearish Trend 1 day ago
87%
BollingerBands
ODDS (%)
Bearish Trend 1 day ago
90%
Bearish Trend 1 day ago
83%
Aroon
ODDS (%)
Bullish Trend 1 day ago
83%
Bearish Trend 1 day ago
84%
View a ticker or compare two or three
Interact to see
Advertisement
AVIR
Daily Signalchanged days ago
Gain/Loss if bought
Show more...
KALV
Daily Signalchanged days ago
Gain/Loss if bought
Show more...
Interesting Tickers
1D
1W
1M
1Q
6M
1Y
5Y
1 Day
MFs / NAMEPrice $Chg $Chg %
GCEBX9.68N/A
N/A
Goldman Sachs Clean Energy Income A
BFTHX59.08N/A
N/A
Baron Fifth Avenue Growth Retail
QBDAX8.33N/A
N/A
Quantified Managed Income Advisor
GFDDX101.71N/A
N/A
Invesco Global R5
MAIFX10.08N/A
N/A
MoA International Fund

AVIR and

Correlation & Price change

A.I.dvisor indicates that over the last year, AVIR has been loosely correlated with IMNM. These tickers have moved in lockstep 47% of the time. This A.I.-generated data suggests there is some statistical probability that if AVIR jumps, then IMNM could also see price increases.

1D
1W
1M
1Q
6M
1Y
5Y
Ticker /
NAME
Correlation
To AVIR
1D Price
Change %
AVIR100%
-1.56%
IMNM - AVIR
47%
Loosely correlated
-6.03%
AXON - AVIR
46%
Loosely correlated
+0.70%
XENE - AVIR
46%
Loosely correlated
-0.12%
MGTX - AVIR
45%
Loosely correlated
+0.61%
KALV - AVIR
44%
Loosely correlated
-0.99%
More

KALV and

Correlation & Price change

A.I.dvisor indicates that over the last year, KALV has been loosely correlated with ATXS. These tickers have moved in lockstep 47% of the time. This A.I.-generated data suggests there is some statistical probability that if KALV jumps, then ATXS could also see price increases.

1D
1W
1M
1Q
6M
1Y
5Y
Ticker /
NAME
Correlation
To KALV
1D Price
Change %
KALV100%
-0.99%
ATXS - KALV
47%
Loosely correlated
+2.14%
IDYA - KALV
47%
Loosely correlated
-0.45%
TRDA - KALV
45%
Loosely correlated
-3.31%
CRSP - KALV
45%
Loosely correlated
+0.19%
ERAS - KALV
45%
Loosely correlated
-3.27%
More